Braun Stacey Associates Inc. Invests $13.33 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)

Braun Stacey Associates Inc. acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 442,805 shares of the biopharmaceutical company's stock, valued at approximately $13,328,000. Braun Stacey Associates Inc. owned about 0.28% of TG Therapeutics as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Creative Planning raised its position in shares of TG Therapeutics by 19.2% during the third quarter. Creative Planning now owns 55,832 shares of the biopharmaceutical company's stock worth $1,306,000 after acquiring an additional 8,993 shares during the last quarter. NBC Securities Inc. raised its position in shares of TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 485 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in shares of TG Therapeutics during the third quarter worth $222,000. Blue Trust Inc. raised its position in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 849 shares during the last quarter. Finally, Raymond James & Associates raised its position in shares of TG Therapeutics by 35.9% during the third quarter. Raymond James & Associates now owns 170,160 shares of the biopharmaceutical company's stock worth $3,980,000 after acquiring an additional 44,972 shares during the last quarter. Institutional investors own 58.58% of the company's stock.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the business's stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the transaction, the chief financial officer now directly owns 670,632 shares of the company's stock, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.50% of the company's stock.

TG Therapeutics Trading Down 0.2 %

NASDAQ:TGTX traded down $0.06 on Friday, reaching $30.88. The company's stock had a trading volume of 1,659,954 shares, compared to its average volume of 2,167,508. TG Therapeutics, Inc. has a 1-year low of $12.90 and a 1-year high of $36.84. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a market cap of $4.81 billion, a PE ratio of -308.77 and a beta of 2.26. The business's 50-day moving average price is $31.07 and its two-hundred day moving average price is $27.73.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TGTX shares. The Goldman Sachs Group boosted their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. TD Cowen started coverage on TG Therapeutics in a research report on Tuesday, October 29th. They set a "buy" rating and a $50.00 target price for the company. StockNews.com cut TG Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, January 31st. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research note on Wednesday, January 15th. Finally, JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research note on Monday, November 25th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.67.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.